Houston's MD Anderson Cancer Center — consistently ranked the world's top cancer hospital — and UTHealth Houston manage some of the most complex mCRPC cases in the United States. For Houston patients seeking affordable access to Abiraterone therapy outside insurance coverage or in private pay situations, Abiranamo 250mg delivers the same proven survival benefit as brand Zytiga at up to 95% lower cost.
Texas has one of the highest rates of uninsured residents in the USA, and Houston's large Hispanic and Latino population — which faces higher prostate cancer mortality rates partly due to later-stage diagnosis and treatment access gaps — particularly benefits from affordable generic Abiranamo making this life-extending therapy financially accessible. MD Anderson's prostate cancer programme is internationally renowned, and many self-funding international patients seeking world-class care in Houston face significant medication cost burdens that generic Abiranamo significantly reduces.
Unnati Pharmax ships to Houston and across Texas with full WHO-GMP documentation. Visit medshopy.com or WhatsApp +91 82650 41513.
Texas has one of the highest rates of uninsured residents in the USA, and Houston's large Hispanic and Latino population — which faces higher prostate cancer mortality rates partly due to later-stage diagnosis and treatment access gaps — particularly benefits from affordable generic Abiranamo making this life-extending therapy financially accessible. MD Anderson's prostate cancer programme is internationally renowned, and many self-funding international patients seeking world-class care in Houston face significant medication cost burdens that generic Abiranamo significantly reduces.
Unnati Pharmax ships to Houston and across Texas with full WHO-GMP documentation. Visit medshopy.com or WhatsApp +91 82650 41513.
What is the LATITUDE trial and how did it change the use of Abiraterone in prostate cancer?The LATITUDE trial (2017) was a landmark study that fundamentally changed Abiraterone prescribing by demonstrating its benefit not just in castration-resistant prostate cancer but also in newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) — i.e. patients who still respond to standard androgen deprivation therapy. Adding Abiraterone plus prednisolone to standard ADT in high-risk mHSPC patients produced a 38% reduction in mortality and a significant improvement in progression-free survival. This trial effectively doubled the population of prostate cancer patients who can benefit from Abiranamo — from those who have progressed on ADT to also include those newly started on ADT with high-risk features. Houston's MD Anderson oncologists now use Abiraterone in both the hormone-sensitive and castration-resistant settings based on this and subsequent trial data.
